Pharma BD Deal Intelligence
Hologic paid $3.8B for Gen-Probe to combine its women's health diagnostics with Gen-Probe's leading molecular testing platforms. The PANTHER system and APTIMA STD assays gave Hologic dominant position in molecular STI diagnostics—a high-volume, recurring-revenue franchise with major barriers to entry.
Hologic acquired Gen-Probe for $82.75 per share in cash (approximately $3.7 billion announced, $3.8 billion net purchase price at close). The deal combined Hologic's women's health diagnostics with Gen-Probe's leading molecular diagnostics platforms (TIGRIS, PANTHER) and APTIMA STD testing franchise.
13.6M US cases/yr · $600M US Blood Screening Market (2012)
Blood screening for HIV, HBV, HCV, and other pathogens is mandatory for all donated blood in the US. Gen-Probe's PROCLEIX system (partnered with Novartis Diagnostics) was the leading nucleic acid testing platform for blood bank screening, offering higher sensitivity than serological methods.
Gen-Probe/Novartis PROCLEIX competed primarily with Roche's cobas TaqScreen MPX for blood bank NAT screening. The blood screening market was a stable, high-margin recurring revenue stream. Post-Hologic acquisition, this business provided predictable cash flows to support growth investments in women's health diagnostics.
Hologic completed $3.8B acquisition of Gen-Probe, combining imaging/surgical platforms with Gen-Probe's molecular diagnostics leadership.
Gen-Probe's Panther molecular diagnostics platform became Hologic's fastest-growing product line in infectious disease and women's health testing.
Combined diagnostics division saw massive COVID-driven acceleration, with Panther platform generating billions in molecular testing revenue.
Transformed Hologic into a diagnostics powerhouse. Panther became multi-billion-dollar franchise amplified by COVID demand. Best diagnostics M&A of the decade.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Hologic, Inc. / Gen-Probe Incorporated (this deal) | 2012 | $3.8B | 78 |
| Hologic, Inc. / Third Wave Technologies, Inc. | 2008 | $580M | 36 |
| Hologic, Inc. / Cynosure, Inc. | 2017 | $1.6B | 12 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
← Browse all deals · How we score deals
More: 2012 deals · Hologic, Inc. deals · Infectious Disease deals